Dr. Ancian has spent the last 20 years in the pharma, biotech and CRO industries where he has implemented and monitored biomarker analyses at the discovery, preclinical and clinical stages with expertise in specialized genomics and proteomics platforms. He holds a PhD in molecular and cellular biology from Nice University as well as an engineering degree in chemistry from the National School of Chemistry of Montpellier, France. Philippe is passionate about advanced therapies, in particular cell and gene therapies.
- Nonclinical evaluation of immunological safety in Göttingen Minipigs: The CONFIRM initiative (ScienceDirect)
- Bone‐ and Cartilage‐Protective Effects of a Monoclonal Antibody Against Colony‐Stimulating Factor 1 Receptor in Experimental Arthritis (Arthritis & Rheumatology)
- 3D modeling and characterization of the human CD115 monoclonal antibody H27K15 epitope and design of a chimeric CD115 target (mAbs)
- Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer (Expert Review of Vaccines)
- A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells (mAbs)